Professor Juan Pablo Kaski co-chaired the brand new European Society of Cardiology Guidelines for the Management of Cardiomyopathies. This is the first international guideline document to include all cardiomyopathy subtypes, and the first time that specific recommendations are made for cardiomyopathies other than hypertrophic cardiomyopathy.

You can access the document on the ESC website by clicking here.

Video: https://medicaldigest.org/scientific-contents/interview:2023-esc-guidelines-management-cardiomyopathies

Professor Josep Redon shares his insights on the special issues the European Society of Hypertension Guidelines covers, focusing on the best treatment options for patients with type-2 diabetes.

Video: https://medicaldigest.org/scientific-contents/interview:what-optimal-treatment-hypertension-diabetics-esh-2023-hypertension-guidelines-diabetes

Professor Peter Nilsson held a lecture on the cardiovascular effects of SGLT-2 inhibitors and GLP-1 agonists, the two new drug classes which revolutionized the treatment of type-2 diabetes at the recent Annual Congress of the European Society of Hypertension.

According to the results:

- SGLT-2 inhibitors and GLP-1 receptor agonists are mostly safe, well-proven and effective drugs to prevent CVD complications and renal impairment/ events in type 2 diabetes patients at high or medium risk.

- GLP-1 RAs are more effective than SGLT-2is to reduce bodyweight, but SGLT-2is are more effective than standard GLP-1 RAs to reduce office and ambulatory BP.

-Recent guidelines suggest using SGLT-2i and GLP1 RA more frequently in patients at high cardiovascular risk, with or without metformin.

Video: https://medicaldigest.org/scientific-contents/interview:diabetes-trials-sglt2-and-glp1-and-their-effects-hypertension

Professor Sverre Erik Kjeldsen explains how the role of the beta-blockers changed a in the new ESH Hypertension guideline.

Video: https://medicaldigest.org/scientific-contents/interview:rehabilitation-beta-blockers-esh-hypertension-guidelines

Professor Otavio Berwanger shares his insight related to the management of patients with hypertension and diabetes.

Video: https://medicaldigest.org/scientific-contents/interview:hypertensive-patients-diabetes-are-raasdiuretic-combinations-foundation-treatment

Professor Gianfranco Parati shares his insight on the new ESH Hypertension guidelines, how we should better manage hypertension in our patients.

Video: https://medicaldigest.org/scientific-contents/interview:managing-hypertension-real-practice-new-esh2023-hypertension-guidelines

Professor Claudio Borghi on the elevated uric acid levels in hypertension. Which patient should be treated, when and how?

Video: https://medicaldigest.org/scientific-contents/interview:hyperuricemia-hypertensive-patients

Professor Renata Cifkova was responsible in the new ESH Hypertension guideline for the topic of hypertension in women. In the interview, she explained what clinicians should know about this important topic.

Video: https://medicaldigest.org/scientific-contents/interview:hypertension-women-underrecognized-issue

Professor Bryan Williams was the driving force behind the 2018 ESH/ESC Hypertension guideline. Many points - including the algorithm for drug therapy - represented a significant step forward for practicing physicians. What changes have been made in the recently presented and published guideline concerning the diagnosis of hypertension and its diagnostic possibilities? Have there been any changes in the treatment algorithm? Has any drug group received more emphasis?

Video: https://medicaldigest.org/scientific-contents/interview:what-has-changed-new-esh-hypertension-guidelines

Dr. Vitoria Cunha explains what is the relationship and effect of hypertension and dyslipidemia on each other? Is it recommended to treat the two risk factors together? How could the combined treatment of the two risk factors be made more accepted and routine among treating physicians? From the perspective of patients, how is it appropriate to communicate the global cardiovascular risk factor management approach? In addition, how can their adherence be improved?

Video: https://medicaldigest.org/scientific-contents/interview:when-hypertension-and-dyslipidemia-co-exist-how-decrease-cv-risk